{"transactions":[{"id":931039,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-26T08:00:07.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":140041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022."}],"balance_after":140041,"derivative":{"exercise_price":4.73,"expiration_date":"2036-01-22","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":140041},"source":{"system":"sec-edgar","filing":"0001193125-26-021729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000119312526021729/ownership.xml","form_type":"4"}},{"id":1304166,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T08:00:07.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":140562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date."}],"balance_after":140562,"derivative":{"exercise_price":6.07,"expiration_date":"2035-01-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":140562},"source":{"system":"sec-edgar","filing":"0000950170-25-004575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000095017025004575/ownership.xml","form_type":"4"}},{"id":1364825,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2024-11-14T18:08:32.000Z","date":"2024-11-14","kind":"purchase","planned":false,"acquired":true,"shares":1800,"price":7.1858,"value":12934.44,"ownership":{"direct":true},"balance_after":8800,"source":{"system":"sec-edgar","filing":"0001493152-24-046106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000149315224046106/ownership.xml","form_type":"4"}},{"id":1489610,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-05T20:00:06.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":70596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months, commencing on July 3, 2024."}],"balance_after":70596,"derivative":{"exercise_price":8.15,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":70596},"source":{"system":"sec-edgar","filing":"0000950170-24-069551","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000095017024069551/ownership.xml","form_type":"4"}},{"id":1661013,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-02T20:00:15.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":81819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in 36 equal monthly installments commencing February 29, 2024, subject to continuous service on each vesting date."}],"balance_after":81819,"derivative":{"exercise_price":5.9,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":81819},"source":{"system":"sec-edgar","filing":"0001493152-24-004815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000149315224004815/ownership.xml","form_type":"4"}},{"id":1983136,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-01T16:05:17.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months commencing on March 27, 2023."}],"balance_after":115000,"derivative":{"exercise_price":3.85,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001493152-23-006389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000149315223006389/ownership.xml","form_type":"4"}},{"id":2066095,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrant to Purchase Common Stock","published_at":"2023-01-04T08:30:19.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reporting Person purchased 7,000 shares of Common Stock and an accompanying warrant to purchase 3,500 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant."}],"balance_after":3500,"derivative":{"exercise_price":7.5,"exercise_date":"2023-01-03","expiration_date":"2025-01-03","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001493152-23-000224","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000149315223000224/ownership.xml","form_type":"4"}},{"id":2066094,"issuer":{"id":6727,"kind":"organization","name":"Coya Therapeutics, Inc."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2023-01-04T08:30:19.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reporting Person purchased 7,000 shares of Common Stock and an accompanying warrant to purchase 3,500 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001493152-23-000224","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000149315223000224/ownership.xml","form_type":"4"}},{"id":3208303,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-16T08:46:43.000Z","date":"2020-03-13","kind":"grant","acquired":true,"shares":230200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in 48 substantially equal monthly installments from March 13, 2020, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":230200,"derivative":{"exercise_price":1.19,"expiration_date":"2030-03-12","underlying":"Common Stock","underlying_shares":230200},"source":{"system":"sec-edgar","filing":"0001698530-20-000020","document":"wf-form4_158436278626721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000169853020000020/wf-form4_158436278626721.xml","form_type":"4"}},{"id":3208302,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-16T08:46:43.000Z","date":"2020-03-12","kind":"purchase","acquired":true,"shares":18248,"price":1.4024,"value":25590.9952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.3650 to $1.43, inclusive. The reporting person undertakes to provide to Exicure, Inc., any security holder of Exicure, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":18248,"source":{"system":"sec-edgar","filing":"0001698530-20-000020","document":"wf-form4_158436278626721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000169853020000020/wf-form4_158436278626721.xml","form_type":"4"}},{"id":3622757,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-01T16:51:57.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 substantially equal monthly installments from February 28, 2019, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":250000,"derivative":{"exercise_price":2.8,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001698530-19-000010","document":"wf-form4_155147710326978.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000169853019000010/wf-form4_155147710326978.xml","form_type":"4"}},{"id":3852841,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-08-03T17:31:34.000Z","date":"2018-08-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 substantially equal monthly installments from August 2, 2018, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."}],"balance_after":100000,"derivative":{"exercise_price":4.97,"expiration_date":"2028-08-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001698530-18-000038","document":"wf-form4_153333187899131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000169853018000038/wf-form4_153333187899131.xml","form_type":"4"}},{"id":4199805,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-09-28T21:40:39.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":12412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in 48 substantially equal monthly installments from December 15, 2016, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."}],"balance_after":12412,"derivative":{"exercise_price":4.21,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":12412},"source":{"system":"sec-edgar","filing":"0000899243-17-022828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000089924317022828/doc4.xml","form_type":"4"}},{"id":4199804,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-09-28T21:40:39.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":19859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in 48 substantially equal monthly installments from February 20, 2015, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."}],"balance_after":19859,"derivative":{"exercise_price":1.03,"expiration_date":"2025-04-28","underlying":"Common Stock","underlying_shares":19859},"source":{"system":"sec-edgar","filing":"0000899243-17-022828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000089924317022828/doc4.xml","form_type":"4"}},{"id":4199803,"issuer":{"id":8068,"kind":"organization","name":"EXICURE, INC."},"owners":[{"id":68781,"kind":"person","name":"SNYDER DAVID S","position":1,"cik":"0001398625","reported_name":"SNYDER DAVID S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-09-28T21:40:39.000Z","date":"2017-09-26","kind":"grant","acquired":true,"shares":374133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested 25% on July 11, 2015, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. (\"Exicure OpCo\"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the \"Conversion Ratio\") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the \"Series C Conversion Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio."}],"balance_after":374133,"derivative":{"exercise_price":0.65,"expiration_date":"2024-10-02","underlying":"Common Stock","underlying_shares":374133},"source":{"system":"sec-edgar","filing":"0000899243-17-022828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398625/000089924317022828/doc4.xml","form_type":"4"}}]}